Sensex, Nifty Extend Losses For Sixth Day Amid IT, Pharma Selloff

Indian equities extended losses for a sixth consecutive session on Friday, with the BSE Sensex falling 0.90% and the NSE Nifty down 0.95%, primarily driven by persistent Foreign Institutional Investor (FII) selling and new U.S. tariff threats. Healthcare stocks experienced significant declines following President Trump's announcement of up to 100% tariffs on branded and patented pharmaceutical imports from October 2025, while IT shares were pressured by Accenture's cautious FY26 guidance and cost restructuring plans, signaling broader sector headwinds.

Analysis

Indian equity markets sustained a significant, broad-based sell-off, with the benchmark BSE Sensex falling 0.90% and the NSE Nifty declining 0.95% to mark a sixth consecutive session of losses. The negative market breadth, with 3,064 shares falling against 1,073 advancing, underscores the pervasive risk-off sentiment, which was driven by persistent Foreign Institutional Investor (FII) selling and adverse geopolitical developments. Two sectors faced acute pressure from distinct, negative catalysts. The healthcare sector experienced heavy losses, with stocks like Dr Reddy's Laboratories and Sun Pharma falling 2-3%, following a U.S. announcement of potential 100% tariffs on branded and patented pharmaceutical imports effective October 2025. This creates substantial future earnings risk, compounded by ambiguity over whether the tariffs will also apply to complex generics. Simultaneously, the IT sector succumbed to selling pressure, with major firms including Infosys and Wipro declining approximately 2%. This was a direct reaction to cautious FY26 guidance and a major cost restructuring announcement from industry bellwether Accenture, signaling potential demand weakness and margin pressure for the entire Indian IT services industry.

Key Decisions for Investors

• Given the sixth consecutive day of declines fueled by FII outflows, investors should consider a defensive posture and closely monitor capital flow data for any reversal before increasing exposure.
• Holders of Indian pharmaceutical stocks with U.S. market exposure must reassess position risk, as the proposed 100% tariff on branded drugs introduces significant long-term uncertainty; clarity on the inclusion of generic and specialty drugs will be a critical future catalyst.
• Accenture's cautious guidance should be viewed as a negative leading indicator for the Indian IT sector, prompting investors to scrutinize upcoming earnings reports from firms like Infosys and Wipro for signs of slowing growth or margin compression.